Effective management of chronic hepatitis B and C requires timely antiviral therapy, accurate liver fibrosis assessment, and structured long-term monitoring. Advances in direct-acting ... Aug 11
Peripheral facial nerve paralysis is an acute neuro-otological condition that demands prompt diagnosis and timely intervention to preserve facial nerve function and improve recovery ... Jul 11
These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic dysregulation, inflammation, and renal progression in type 2 ... Oct 31
As India continues its journey towards becoming the diabetes capital of the world, the medical fraternity faces the challenge of changing old habits both in ... Oct 08
... Apr 15
... Mar 20
Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801).... Sep 11
Latest Corporate news updates; Pharma Feb 3rd 2022... Feb 03
Latest Pharma News update... Sep 03
Latest Pharma News Update... Aug 31
Latest Pharma Update... Aug 23
FDA News Update... Aug 05
... Jul 17
Immutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021. ... Jul 12
Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Treatments in BRCA1/2-Mutated Advanced Prostate Cancer... Jun 24
First medicine approved in the EU to treat this rare and debilitating genetic condition... Jun 22
With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG.... Jun 14
Significantly improves progression-free Survival vs. Opdivo (nivolumab) in patients... May 22
GSK's Covid product could be soon in the market after the emergency medical application review... May 11
Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options... May 08
The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE ... Mar 27
CAPLYTA (lumateperone)is indicated for the treatment of Bipolar Depression... Feb 23
Approval comes after Failure of at Least Two Lines of Prior Systemic Therapy... Feb 22
Compugen Ltd expands collaboration agreement with Bristol Myers Squibb with phase 1b combination study of COM701 with opdivo C... Feb 22
-Advertisements-